Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Coffee Shoppe
(Total Views: 98)
Posted On: 03/23/2017 7:35:54 PM
Post# of 63831
Avatar
Posted By: PoemStone
Re: Go Green #47973
$IMMU stair steps 5 months
Upper bollie $6.63
Nasdaq GM

Website
g493318logo.jpg

Last ten trades


10-Q 2/10/17
1642481658_otc.jpeg

80% x 100% Strong Buy
850318709_barchart_logo1.jpg

Shares Outstanding 106.08M
Float 89.45M

% Held by Insiders 6.84%
% Held by Institutions 43.70%
Shares Short 3 21.88M
Short Ratio 4.12
Short % of Float 21.98%
Shares Short (prior month) 23.57M


Stock technical analysis

895828223_stockta5.jpg

News
and filings

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.


bottomphoto22.png

Pipeline3.jpg

(0)
(0)






Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP




  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site